Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLeAR: Cemiplimab +/- Fianlimab After Y90 in HCC
NCT07365839Phase 1Withdrawn
- Sponsor
- Virginia Commonwealth University
- Start
- Oct 2026
- Primary completion
- May 2035
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 1, randomised, open-label trial of fianlimab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Virginia Commonwealth University. Primary endpoint: Progression-Free Survival. Planned start Oct 2026; status: withdrawn.
02
Drugs
fianlimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07365839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07365839.